What impact does insulin resistance have on cutaneous perfusion responses to insulin iontophoresis in vascular beds with markedly reduced or functionally ablated sympathetic nervous system vasomotor function resulting from spinal cord injury? r What is the main finding and its importance?
Introduction
Neuromotor and cardiovascular autonomic interruption after spinal cord injury (SCI) contributes to adverse changes in soft-tissue body composition and arterial vasculature adaptations that predispose individuals to the development of sublesional microcirculatory dysfunction (Olive et al. 2003; West et al. 2013) . Supraspinal control of sympathetic cardiovascular autonomic outflow is dramatically attenuated or fully ablated below the neurological level of the lesion (Wecht et al. 2015) . Over time, this deficit of neural outflow contributes to a downregulation and reduction of α-and β-adrenergic receptors in the sublesional vascular beds (Rodriguez et al. 1986 ). This maladaptation would be speculated to limit the capacity to recruit perfusion through vasomotor activation of the neurologically intact (i.e. residual) cutaneous circulation (Rodriguez et al. 1986) . The density of these receptors and how they respond to provocation are anticipated to reflect the degree of residual sympathetic activity of the insensate cutaneous microcirculation (Bernjak et al. 2011) . However, the dearth of adrenergic receptors (Rodriguez et al. 1986 ), a reduction to basal and inducible plasma catecholamines (Mathias et al. 1975) and the presence of endothelium-associated dysfunction (Boot et al. 2002; Olive et al. 2003; de Groot et al. 2004 de Groot et al. , 2005 de Groot et al. , 2006 Bleeker et al. 2005; Thijssen et al. 2005 Thijssen et al. , 2008 La Fountaine et al. 2013; Totosy de Zepetnek et al. 2015a,b) could be speculated to limit the latency and magnitude of vasomotor responses to periods of reduced cutaneous perfusion. Thus, the sensitivity of intact and residual endothelium-mediated mechanisms that regulate skin blood flow might play an integral role to maximize the capacity to maintain appropriate basal levels of perfusion and to reperfuse tissues adequately (i.e. postocclusive hyperaemia).
Insulin is a vasoactive hormone and second messenger of nitric oxide (Kahn et al. 2000) that facilitates endothelium-mediated vasodilatation adjacent to receptors bound by insulin. In insulin-sensitive (IS) individuals, the vasodilatory effects of insulin are largely dependent on the release of nitric oxide from the endothelium and on the secondary withdrawal of sympathetic nervous system (SNS) vascular tone (Vollenweider et al. 1993; Sartori et al. 1999; Eringa et al. 2002; Tousoulis et al. 2008) . In the presence of insulin resistance (IR) and/or endothelial dysfunction of varying aetiology (i.e. resulting in a reduced release of and sensitivity to nitric oxide), the decreased end-organ action of insulin contributes to a comparative reduction to perfusion, relative to the sensitive state (Laakso et al. 1990) . In a previous report by our group, persons with SCI who had normal fasting plasma glucose (FPG) concentrations and efferent SNS impairment below the level of the lesion had dramatically lower cutaneous perfusion responses to transdermal insulin than matched able-bodied (AB) subjects (La Fountaine et al. 2013) . These findings indicated a state of subclinical endothelial dysfunction and reduced insulin sensitivity of the microvasculature in a population that is appreciated to have an increased prevalence of insulin resistance attributable to physical inactivity and increased adiposity (Bauman & Spungen, 1994 Bauman et al. 1999a ).
The present investigation determined the role of insulin resistance in cutaneous perfusion responses to insulin iontophoresis in vascular beds with markedly reduced or functionally ablated SNS vasomotor function resulting from SCI. Neurologically intact and demographically matched participants were recruited to participate to serve as control subjects. We also determined endothelial function by performing acetylcholine iontophoresis in the same vascular beds. Acetylcholine is considered to be the gold standard to assess endothelium-dependent vasodilatation of the microvasculature non-invasively (Lekakis et al. 2011) , and this pathway has been demonstrated to be the same for insulin (Johnstone et al. 1993) . Thus, cutaneous perfusion responses to acetylcholine provocation would represent the theoretical peak perfusion capacity of the corresponding vascular bed and serve as the appropriate endothelium-mediated comparator for insulin. We hypothesized that the presence of insulin resistance in the SNS-dysfunctional lower extremity of persons with SCI would result in the lowest cutaneous perfusion responses to insulin and acetylcholine iontophoresis compared with other groups.
Methods
The study was independently approved by the Institutional Review Board (approval number LAF-12-018) at two study sites and conformed to the standards set by the Declaration of Helsinki. Written informed consent was obtained from each subject before participation in the study. This was a prospective, open-label, randomized, placebo-controlled and parallel-group intervention and observation trial to determine the comparative cutaneous blood perfusion responses to endothelium-mediated vasomotor agonists among insulin-sensitive and insulin-resistant individuals with or without SNS impairment (ClinicalTrials.gov identifier: NCT02034331). All subjects completed a medical history inclusive of demographics (i.e. age, height, weight and ethnicity) and injury specifics (i.e. level of neurological injury, duration of injury and the extent of motor deficit below the level of injury) and had fasting venous blood samples collected for the determination of homeostatic model assessment of insulin resistance (HOMA-IR) (Levy et al. 1998 ) on a separate visit from iontophoresis procedures. Participants were characterized as being insulin sensitive (<13.13 mIU ml −1 ) or insulin resistant (ࣙ13.13 mIU ml −1 ) based upon fasting plasma insulin (FPI) concentrations (Kim-Dorner et al. 2010) . The effects of insulin, acetylcholine or placebo (i.e. normal saline) were quantified using laser Doppler flowmetry (LDF Probe 481-1; Periflux System 5000; Perimed, Stockholm, Sweden) during the separate transdermal delivery by iontophoresis (PF 750, PeriIont Micropharmacology System; Perimed) in the legs of persons with SCI and intact able-bodied individuals. The respective blood perfusion unit responses were compared and contrasted across four group designations: able bodied, insulin sensitive (ABIS); able bodied, insulin resistant (ABIR); spinal cord injury, insulin sensitive (SCIS); and spinal cord injury, insulin resistant (SCIR). The use of iontophoresis to deliver insulin transdermally was approved by the US Food and Drug Administration under an Investigational New Drug application.
Subjects
Thirty-two persons with non-ambulatory, motorcomplete [i.e. American Spinal Injury Assessment Impairment Scale (AIS) designation of A or B], chronic SCI (>6 months post-SCI) and 30 AB individuals were randomly recruited for participation from the SCI Service, outpatient clinics and hospital staff of the James J. Peters Veterans Affairs Medical Center, Bronx, NY and the Kessler Institute for Rehabilitation, West Orange, NJ and assigned to an IS or IR subgroup as previously described. Men and women between the ages 20 and 69 years were considered for study eligibility as an AB control or SCI subject if they were free of acute medical illness (i.e. not receiving treatment for an active medical condition), were without diagnosed chronic illness (i.e. atherosclerosis, congestive heart failure, history of myocardial infarction or previous diagnosis of diabetes mellitus or IR) and had the capacity to provide informed consent. No subjects were taking medications with known effects on any of the study-related outcome measurements, and no participants were asked to discontinue the use of any medications for the purpose of study enrolment. Exclusion criteria were as follows: (i) diabetes mellitus and/or receiving treatment with insulin, insulin-sensitizing agents, or agents that alter pancreatic secretion of insulin; (ii) receiving treatment with sympathomimetic agents demonstrating direct vascular actions or indirect implications (i.e. α 1 agonists, cholinesterase inhibitors, noradrenaline, calcium channel blockers, angiotensin-converting enzyme inhibitors); or (iii) moderate-to high-dose glucocorticoid administrations (i.e. ࣙ40 mg prednisone or equivalent daily steroid dose) within the past 3 months.
Data collection
The subjects arrived at the laboratory in the morning after abstaining from food, caffeinated and/or alcohol-containing beverages for the previous 8 h. Able-bodied and lower cord injury subjects were positioned (transferred) supine on a standard hospital bed; higher cord injury individuals were transferred to a hospital bed or, in a few circumstances, were reclined to a supine position in their power chair. To mitigate hydrostatic gradients, the effective test position for the limb was at the level of the heart. All testing was completed in a temperature-controlled room (22°C).
The legs were uncovered of apparel/garments below the knees, with attention given to ensure that no clothing items constricted blood flow to the limb. For treatment with each agent, the placements of active and return electrodes were standardized. The active LDF/iontophoresis electrode (LDF Probe 481-1 with PF 383 Drug Delivery Electrode; Periflux System 5000; Perimed) was placed and secured with the manufacturer's proprietary dual-sided adhesive electrode; the return electrode (PF 384; Perimed) contained a medical-grade adhesive for skin securement. The effective surface area for treatment by the iontophoresis electrode was 1.27 cm 2 . The return electrode was placed 7.62 centimeters proximal to the lateral malleolus, and the active electrode was placed 15.24 centimeters proximally over the belly of the peroneus longus and tibialis anterior muscles (Fig. 1) . The emphasis on 6 inches distance between active and return electrodes is considered standard practice for iontophoresis and obviates the risk for shock. Using an integrated LDF and iontophoresis system (LDF Probe 481-1 with PF 383 Drug Delivery Electrode; Periflux System 5000; and PF 750, PeriIont Micropharmacology System; Perimed), cutaneous blood perfusion responses were evaluated while the respective agent was simultaneously delivered. The vasoactive agents (i.e. insulin or acetylcholine) were delivered unilaterally on separate applications, while the placebo intervention (i.e. preservative-free normal saline) was simultaneously performed on the contralateral leg. Each application of agent/placebo by iontophoresis was 18 min in duration and separated by a minimum of 30 min to avoid the possibility of residual effects from the previous provocation. If there was any evidence of a protracted cutaneous perfusion response from the previous trial (i.e. redness of skin, increased tissue temperature, increased relative blood perfusion via LDF), testing with the subsequent agent was delayed until the area was restored to its baseline conditions.
For insulin and placebo iontophoresis, the cathode pole was the active electrode and contained 0.2 ml of liquid insulin (Humulin R, 100 units ml −1 ; Eli Lilly and Co., Indianapolis, IN, USA) or 0.2 ml of placebo (i.e. preservative-free normal saline), respectively (Serné et al. 2002; Rossi et al. 2005; de Jongh et al. 2008; La Fountaine et al. 2013) . For acetylcholine iontophoresis, the anode pole was the active electrode and contained 0.2 ml of 1% acetylcholine (acetylcholine chloride; Sigma-Aldrich, Co. LLC, St Louis, MO, USA; Lekakis et al. 2011) . A continuous 0.2 mA current was applied to the active electrode for 18 min to deliver the respective agent (i.e. acetylcholine, insulin or placebo) for all transdermal iontophoretic treatments. Cutaneous blood perfusion unit (BPU) responses from LDF of each recording were obtained in arbitrary units, and the signals were collected with a 0.03 s time constant.
Data processing
Two minutes of representative baseline (i.e. preiontophoresis) BPU data were obtained for each evaluation. Likewise, the peak cutaneous BPU response was identified for each evaluation, and a representative 2 min data sample was isolated; it was most common that 1 min before and after the peak BPU response was used. The mean baseline and peak BPU responses were determined for each evaluation, and the percentage change was calculated [i.e. (peak − baseline)/baseline × 100]; each agent (i.e. acetylcholine, insulin or placebo) was represented by a single percentage change response. In agreement with pharmacodynamic practices to aid comparison between agents of varying dose concentrations and differing mechanisms, each BPU percentage change response was log 10 transformed. Insulin was prepared as a solute in preservative-free normal saline. Therefore, the net insulin response (NetIns) was calculated to determine the independent contribution of the insulin response relative to placebo, which was a solution that contained a cation with vasoactive potential (i.e. sodium chloride); to calculate NetIns, the log 10 -transformed BPU percentage change response for placebo was subtracted from the corresponding BPU percentage change response to insulin. This calculation was not performed for acetylcholine because the agent is negatively charged and was delivered to the skin with the anode electrode. At the time of data processing, the observer was blind to the insulin group assignment, because laboratory results would have been pending.
Blood sampling and analysis
All participants had blood sampled from the antecubital vein for determination of FPG and FPI concentrations before iontophoresis. The blood samples were spun down in a refrigerated centrifuge, separated and frozen at −20°C until batch processing upon completion of the entire study (i.e. FPI) or immediately processed by the core laboratory (i.e. FPG). The FPG was determined using a commercially available analyser (YSI 2300 Stat Plus; YSI Incorporated, Yellow Springs, OH, USA), in accordance with the manufacturer's guidelines. Analysis for FPI concentrations were batch processed in duplicate by radioimmunoassay (Berson & Yalow, 1966) .
Statistics
Values are expressed as the group mean with SD as stated in the figure legend or table footnote. Separate factorial ANOVA was performed to identify the presence of group differences in subject demographics, fasting blood profiles and HOMA-IR and, for SCI only, the duration of injury.
Pearson χ 2 tests were performed to determine whether the SCIS and SCIR groups differed in the composition of AIS designation between subgroups. For LDF outcomes, separate mixed-model ANOVA was performed to identify group differences (i.e. ABIS × ABIR, SCIS × SCIR) within and between provocations (i.e. acetylcholine, insulin or placebo) for the respective log 10 BPU responses. The 'within-provocation' statistical evaluation determined whether the respective group log 10 BPU percentage change was significantly different from the null hypothesis (i.e. no change). The subsequent 'between-provocation' statistical evaluation determined whether the respective group log 10 BPU percentage changes were significantly different from one another. Separate factorial ANOVAs were performed with Bonferroni post hoc analyses to determine whether the NetIns responses was different between groups (i.e. ABIS, ABIR, SCIS, SCIR). Separate Student's paired t tests (i.e. ABIS versus ABIR, SCIS versus SCIR, ABIS versus SCIS, ABIS versus SCIR) were performed to determine whether the NetIns and BPU responses to acetylcholine (i.e. NetIns/acetylcholine) were different within subgroups. An a priori level of significance was set at P ࣘ 0.05. Statistical analyses were completed using IBM SPSS Statistics 21 (IBM, Armonk, NY, USA).
Results

Comparison of demographics
The groups were not different for age, height, weight and FPG (Table 1) . Body mass index trended towards a significant group difference, but it was found not to be a significant contributor to any of the statistical models. By study design, FPI and HOMA-IR were different in the respective comparisons within and between the two IS and two IR subgroups (Table 1) . The SCIS and SCIR subgroups were matched for AIS classifications. The SCIR group had Insulin resistance and cutaneous perfusion Data are expressed as group means (SD). Significant or trending differences from within-group comparisons (able bodied or spinal cord injury): * P < 0.05 and † P = 0.08. The P-values represent significant group main effects for between-group comparisons. Post hoc analyses for significant between-group comparisons: ‡ able-bodied insulin-sensitive versus spinal cord injury insulin-sensitive group, P < 0.05; and § able-bodied insulin-sensitive versus spinal cord injury insulin-resistant group, P < 0.05.
a significantly longer duration of injury than the SCIS. In a post hoc analysis, the duration of injury was found to have no effect on the observed BPU outcomes and was, therefore, excluded for use as a covariate in further analyses.
Within-group comparisons of BPU responses to agents
Within each group (i.e. ABIS, ABIR, SCIS, SCIR), BPU percentage change responses to the agents (i.e. acetylcholine, insulin, placebo) were compared. In the ABIS group, the BPU responses to acetylcholine and insulin were significantly greater than that of placebo (P < 0.05 and P < 0.0001, respectively), and there was no difference between insulin and acetylcholine responses (Table 2 ). In the two IR subgroups, neither vasoactive agent (i.e. acetylcholine or insulin) produced a BPU response that differed from the response to placebo. In the SCIS group, the mean insulin BPU response was greater than the response to placebo (P < 0.0001), and the mean acetylcholine response was not different from the response to placebo.
Between-group comparisons of BPU responses to agents
In analyses between subgroups (i.e. ABIS versus ABIR and SCIS versus SCIR), BPU percentage change responses to the agents (i.e. acetylcholine, insulin, placebo) were compared ( Table 2 ). The BPU response to insulin was significantly greater in the SCIS group compared with the SCIR group, a finding that was not observed in the able-bodied group comparison. The corresponding comparisons for acetylcholine BPU responses were not significantly different for the SCI subgroups, but trended towards a greater response in the ABIS group compared with ABIR. The NetIns response was significantly greater in both IS groups compared with their respective IR group (Fig. 2) . The acetylcholine-mediated BPU responses were similar to one another and to the ABIR group, and the BPU responses of the two SCI subgroups were significantly lower than that of the ABIS group (Table 2) , suggesting the presence of some degree of endothelial dysfunction. The NetIns and acetylcholine BPU responses were compared within groups (Fig. 3) . For each subgroup except SCIS, the acetylcholine BPU responses were significantly greater than NetIns (P < 0.05). In the ABIS and SCIS groups, the NetIns BPU group response was ß48 and ß81%, respectively, of the acetylcholine group response, but the ABIR and SCIR groups had a markedly lower NetIns BPU response of 2 and 24%, respectively.
Discussion
This work has improved our understanding of the way in which IR affects cutaneous blood perfusion in the lower extremities of persons with SCI. The presence of SNS dysfunction and a loss of functional innervation in sublesional vascular beds secondary to SCI is assumed to result in a greater dependence on and role for vasoactive substances that target the endothelium to modulate cutaneous perfusion. In addition to its primary effect on glucose uptake, insulin, a second messenger for nitric oxide (Kahn et al. 2000) , has haemodynamic actions in the vasculature by targeting the endothelium (Laakso et al. 1990; Scherrer et al. 1994; Steinberg et al. 1994; Baron et al. 1995 Baron et al. , 2000 Serné et al. 2002; Rossi et al. 2005; de Jongh et al. 2008; La Fountaine et al. 2013) . Therefore, insulin and endothelial responsiveness to its actions have the potential to play a pivotal role in the modulation of cutaneous perfusion in the sublesional vasculature of persons with SCI. There were several findings of interest in the present study that support our hypothesis. The present findings build upon our previous report (La Fountaine et al. 2013) by demonstrating the added confounding and deleterious effects of the IR state on inducible cutaneous BPU responses to insulin iontophoresis in persons with SCI. The presence of IR, as defined by the clinical threshold for FPI (Kim-Dorner et al. 2010) , confounded sublesional cutaneous BPU NetIns responses to iontophoresis in both AB and SCI participants compared with IS individuals. Finally, persons with SCI, independent of being characterized as IR or IS, have a blunted cutaneous BPU response to acetylcholine iontophoresis, providing evidence for endothelial dysfunction. Macrovascular endothelial dysfunction has long been associated with the incidence and progression of cardiovascular disease (Celermajer et al. 1992) . There are numerous previous reports in persons with SCI that describe sublesional macrovascular remodelling (i.e. compensatory reduction to cross-sectional area of the arterial tree with lean tissue atrophy) and its contribution to endothelial dysfunction (Boot et al. 2002; Olive et al. 2003; de Groot et al. 2004 de Groot et al. , 2005 de Groot et al. , 2006 Bleeker et al. 2005; Thijssen et al. 2005 Thijssen et al. , 2008 Totosy de Zepetnek et al. 2015a,b) . There is no evidence to suggest that the endothelial dysfunction observed in these reports was a consequence of reduced nitric oxide bioavailability, but instead it is speculated to be a reflection of endothelial responsiveness to the presence of nitric oxide, which upon inhibition has been demonstrated to result in marked increases in peripheral vascular resistance (La Fountaine et al. 2009 ). The presence of microvascular endothelial dysfunction is associated with an increased risk for cardiovascular-related disease, which has been reported as one of the primary causes of death after the first post-injury year (DeVivo et al. 1992; Garshick et al. 2005; Wahman et al. 2010; Chen et al. 2013; Cragg et al. 2013) . Endothelial dysfunction has also emerged as a probable link between atherosclerosis and IR (Haffner et al. 1990; Reddy et al. 2010) , which occurs at an increased prevalence in persons with SCI (Bauman & Spungen, 1994; Bauman et al. 1999a,b; Bauman & Spungen, 2001) . Thus, the presence of sublesional macrovascular endothelial dysfunction in persons with SCI is indicative of a heightened risk for multiple system morbidity and adverse health outcomes.
It is unlikely that macrovascular endothelial dysfunction can occur without evidence for its presence in the microcirculation, as well (Urbančič-Rovan et al. 2006) . Appreciating that acetylcholine is considered to be the gold standard to assess endothelium-dependent vasodilatation of the microvasculature non-invasively (Lekakis et al. 2011) , BPU responses to the provocation would represent the theoretical peak perfusion capacity of the cutaneous vascular bed. Our new findings in persons with SCI demonstrate the presence of sublesional microvascular endothelial dysfunction that is exacerbated by IR in the skin. An investigation in persons with SCI using LDF technology by Li et al. (2006) demonstrated a reduction to resting skin blood flow oscillations (compared with able bodied) in the frequency spectra associated with endothelial activity (0.01-0.02 Hz); oscillations in this frequency range are inducible by acetylcholine iontophoresis (Kvernmo et al. 1999) . Cutaneous BPU responses to acetylcholine iontophoresis were lower in our ABIR group than those of the ABIS group, a finding that is in agreement with an earlier investigation in non-diabetic women with or without IR (Pienaar et al. 2014) . However, the same relationship was not found in our SCI groups, who had similar BPU responses to acetylcholine iontophoresis as the ABIR group. This blunted BPU response, when compared with the ABIS group, suggests that a subclinical state of microvascular endothelial dysfunction was present and is a likely consequence of extreme physical inactivity and post-SCI macrovascular remodelling (Olive et al. 2003; de Groot et al. 2006) . Given that endothelium-mediated vasodilatation that occurs in response to insulin relies on the withdrawal of SNS vascular tone to maximize the response (Vollenweider et al. 1993; Sartori et al. 1999; Eringa et al. 2002; Tousoulis et al. 2008) , the absence or impairment of functional SNS innervation to the lower extremity vasculature may be speculated to have contributed to the attenuation of the NetIns response in all SCI participants (Serné et al. 2002; Rossi et al. 2005; de Jongh et al. 2008) . This outcome was more adversely affected by the presence of IR. The role of residual sublesional SNS innervation on endothelium-mediated improvements (i.e. acetylcholine responses) to cutaneous perfusion appears to be negligible. When comparing the proportion of insulin and acetylcholine responses with one another, the impact of IR on endothelium-mediated recruitment of perfusion becomes more apparent. The collective findings highlight the vital role of endothelial sensitivity to the actions of insulin in optimizing the inducible skin perfusion capacity in the lower extremity of those with IR.
The concept of endothelial sensitivity to the haemodynamic actions of insulin in the lower extremities has substantial implications for persons with SCI; in particular, on the genesis of skin breakdown and formation of pressure ulcers. Nearly 40% of individuals with SCI experience hospitalization for treatment of pressure ulcers during the initial 20 years of injury (DeLisa & Mikulic, 1985; Regan et al. 2009) , and up to 85% of individuals report the occurrence of at least one pressure ulcer since being injured (Sumiya et al. 1997) . A comprehensive review of the pressure ulcer SCI literature identified 200 risk factors that contribute to the genesis of skin breakdowns and pressure ulcer formation (Byrne & Salzberg, 1996) . Among the numerous potential physical risk factors identified were several conditions that may be collectively characterized as having a significant confounding effect on the cutaneous microcirculation, including impaired glycaemic control (Byrne & Salzberg, 1996) . The role of endothelial sensitivity to the haemodynamic actions of insulin in tissues prone to skin breakdown has yet to be described. However, it is clinically important to understand that endothelial function is modifiable and can be improved if an effective screening strategy has been identified and deployed.
Interventions of varying duration that use different modes of exercise have been designed and implemented in persons with SCI. There is general agreement that beneficial adaptations to training conditions can lead to improvements in sublesional macrovascular endothelial function, whether or not increases in lean tissue mass occur in parallel (Olive et al. 2003; de Groot et al. 2005; Thijssen et al. 2005; Totosy de Zepetnek et al. 2015b) . Likewise, there is evidence for improved cutaneous and muscle microvascular perfusion responses to acute bouts of exercise in persons SCI (Muraki et al. 1995 (Muraki et al. , 1996 Theisen et al. 2001; Van Duijnhoven et al. 2009; Zafeiridis et al. 2012) , an important mechanism to promote positive endothelial adaptations to exercise, but there is still insufficient evidence for exercise intervention to result in improved cutaneous perfusion through augmented endothelial function. Lifestyle modifications have been found to improve local vasodilatory responses to insulin iontophoresis among individuals with the metabolic syndrome (Vinet et al. 2015) , but the same has yet to be demonstrated in persons with SCI. A recent report that addressed subclinical endothelial dysfunction in individuals who displayed a deficit in glucose metabolism demonstrated that a short course of treatment with a peroxisome proliferator-activated receptor γ agonist enhanced peripheral IS and resulted in a marked improvement in endothelium-mediated vasodilatation (Quinn et al. 2010) . There is no evidence to indicate that persons with SCI, as a group, would be refractory to exercise interventions, routine physical activity or standard pharmacological interventions to improve or manage IS, which would collectively be assumed to result in improved endothelial health. These interventions would be anticipated to maximize the capacity of inducible endothelium-mediated vasodilatation of cutaneous perfusion. The challenge is to implement a clinically appropriate approach to screen for risk, identify those with microvascular endothelial dysfunction and introduce an effective intervention.
Conclusions
Persons with SCI have sublesional microvascular endothelial dysfunction, as indicated by a blunted cutaneous perfusion response to acetylcholine iontophoresis. The presence of IR has a further confounding effect on endothelium-mediated changes to cutaneous perfusion in the lower extremities of persons with SCI. Preventing the development and modulating the presence of IR appears to be an important modifiable risk factor for the optimization of cutaneous perfusion in persons with SCI.
